首页分子通3-[2-[[[1-(2-cyclohexylethyl)-5-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]-6-methoxy-4,5-dimethyl-1H-indol-1-yl]propionic acid ethanolamine salt
3-[2-[[[1-(2-cyclohexylethyl)-5-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]-6-methoxy-4,5-dimethyl-1H-indol-1-yl]propionic acid ethanolamine salt | 418771-02-5
3-[2-[[[1-(2-cyclohexylethyl)-5-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]-6-methoxy-4,5-dimethyl-1H-indol-1-yl]propionic acid ethanolamine salt
TRIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
申请人:SANOFI-SYNTHELABO
公开号:EP1335914A1
公开(公告)日:2003-08-20
[EN] TRIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE TRIAZOLE ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
申请人:SANOFI SYNTHELABO
公开号:WO2002034743A1
公开(公告)日:2002-05-02
The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, solvates, hydrates and polymorphs. These compounds are powerful and selective CCK1 receptor agonists.